AFX logo

Carl Zeiss Meditec AG Stock Price

XTRA:AFX Community·€2.4b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 69 Fair Values set on narratives written by author

AFX Share Price Performance

€0
-50.35 (-100.00%)
€28.63
Fair Value
€0
-50.35 (-100.00%)
Price €0

AFX Community Narratives

·
Fair Value €28.63 3.0% undervalued intrinsic discount

VISUMAX 800 Approval In China Will Strengthen Future Market Position

1users have liked this narrative
0users have commented on this narrative
35users have followed this narrative
·
Fair Value €42.73 35.0% undervalued intrinsic discount

Digital And AI Advances Will Expand Global Eye Care Markets

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
·
Fair Value €22.4 24.0% overvalued intrinsic discount

Regulatory Uncertainty And Trade Tensions Will Depress Margins

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
€28.63
3.0% undervalued intrinsic discount
Revenue
5.06% p.a.
Profit Margin
8.55%
Future PE
13.61x
Price in 2029
€33.81
€42.73
35.0% undervalued intrinsic discount
Revenue
11.11% p.a.
Profit Margin
8.21%
Future PE
17.93x
Price in 2029
€50.6
€22.4
24.0% overvalued intrinsic discount
Revenue
2.32% p.a.
Profit Margin
7.01%
Future PE
10.89x
Price in 2029
€26.82

Trending Discussion

No trending discussion available.

Updated Narratives

AFX logo

AFX: Fair Outlook As New Leadership And VR Partnership Shape Prospects

Fair Value: €28.63 3.0% undervalued intrinsic discount
35 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
AFX logo

AFX: New Lens Launch And Margin Reset Will Support Future Upside

Fair Value: €42.73 35.0% undervalued intrinsic discount
2 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
AFX logo

AFX: Lowered Guidance And China Tender Pressures Will Reshape Medium Term Risk Reward

Fair Value: €22.4 24.0% overvalued intrinsic discount
3 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Excellent balance sheet, good value and pays a dividend.

2 Risks
2 Rewards

Carl Zeiss Meditec AG Key Details

€2.2b

Revenue

€1.1b

Cost of Revenue

€1.1b

Gross Profit

€1.0b

Other Expenses

€94.9m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 06, 2026
1.08
51.28%
4.37%
21.6%
View Full Analysis

About AFX

Founded
1846
Employees
5798
CEO
Andreas Pecher
WebsiteView website
www.zeiss.com/meditec-ag/de/investor-relations.html?vaURL=www.zeiss.de/meditec-ag/ir

Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for retina examination; functional glaucoma diagnostic devices (perimeters); surgical ophthalmology products comprising surgical microscopes, biometers, and phacoemulsification and vitrectomy equipment; intraocular lenses for cataract surgery; and systems and consumables for laser eye surgery that include the VISUMAX femtosecond laser, which enables minimally invasive correction of vision defects using lenticular extraction, as well as digital products for the storage, analysis, and sharing of clinical data. The Microsurgery segment provides products and solutions for minimally invasive surgical treatments, including surgical visualization, interoperative radiotherapy, interoperative pathology, special surgical instruments, and digital solutions, as well as the ZEISS Tumor Workflow, a cross-product workflow solution. It serves physicians in various fields and hospitals. The company has a strategic collaboration with Envision Health Technologies Inc. to help advance glaucoma care through gamified virtual reality technology. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG operates as a subsidiary of ZEISS Group.

Recent AFX News & Updates

Narrative Update Jul 09

AFX: Fair Outlook As New Leadership And VR Partnership Shape Prospects

The analyst price target for Carl Zeiss Meditec has been reduced from about €30.19 to about €28.63, with analysts citing a lower Street target of €21.70 and modest adjustments to growth, profitability, and P/E assumptions as key factors behind the move. What’s in the News for Carl Zeiss Meditec Carl Zeiss Meditec, through ZEISS Medical Technology, announced a collaboration with Envision Health Technologies to use gamified virtual reality tools in glaucoma care.
Narrative Update Jun 16

AFX: New Lens Launch And Margin Reset Will Support Future Upside

Analysts have trimmed their price target on Carl Zeiss Meditec to €21.70 from €22.40, reflecting updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E multiples. What’s in the News for Carl Zeiss Meditec ZEISS Medical Technology reported successful early clinical implantations of the ZEISS AT LUCIA toric 721P intraocular lens for cataract treatment and astigmatism correction across six European countries, with positive surgeon feedback.

Recent updates

No updates